Clinical trials recruiting for Metastatic Non Small Cell Lung Cancer

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
  NCT06066138 · Phase: Phase 1 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT07154290 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT06417814 · Phase: Phase 3 · Ages: 18 Years to 130 Years · Sex: All (male and female) · 303 locations
• Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
  NCT04614103 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 71 locations
• Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer
  NCT07008742 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
  NCT06216301 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 98 locations
• MOv19-BBz CAR T Cells in FRa+ Cancers
  NCT07116057 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
  NCT04410796 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
  NCT04613596 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 770 locations
• Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer
  NCT05985330 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
  NCT06731413 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety and Efficacy of OBX-115 in Advanced Solid Tumors
  NCT06060613 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 10 locations
• Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer
  NCT07689643 · Phase: Early Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC
  NCT05278052 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · 1 location
• Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer
  NCT06523673 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
  NCT07185997 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT07222566 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 440 locations
• The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients
  NCT06428422 · Phase: Not applicable (e.g. observational or device study) · Ages: 19 Years to 90 Years · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Metastatic Non Small Cell Lung Cancer often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Metastatic Non Small Cell Lung Cancer trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.